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SUMMARY
Growing evidence supports the importance of gut
microbiota in the control of tumor growth and
response to therapy. Here, we select prebiotics
that can enrich bacterial taxa that promote anti-tu-
mor immunity. Addition of the prebiotics inulin or
mucin to the diet of C57BL/6 mice induces anti-tu-
mor immune responses and inhibition of BRAF
mutant melanoma growth in a subcutaneously
implanted syngeneic mouse model. Mucin fails to
inhibit tumor growth in germ-free mice, indicating
that the gut microbiota is required for the activation
of the anti-tumor immune response. Inulin and
mucin drive distinct changes in the microbiota, as
inulin, but not mucin, limits tumor growth in synge-
neic mouse models of colon cancer and NRAS
mutant melanoma and enhances the efficacy of a
MEK inhibitor against melanoma while delaying the
emergence of drug resistance. We highlight the
importance of gutmicrobiota in anti-tumor immunity
and the potential therapeutic role for prebiotics in
this process.
INTRODUCTION
Melanoma remains one of the most aggressive tumor types,
mainly because of its propensity to metastasize and resist
therapy. Aberrant activation of the mitogen-activated protein
kinase (MAPK) pathway has been reported in human BRAF
and NRAS mutant tumors, including melanomas, in which
they account for more than 70% of genetic changes. Although
selective inhibitors to BRAF mutant proteins have been devel-
oped, their effectiveness is limited by the frequent emergence
of resistance (Brighton et al., 2018; Fedele et al., 2018; Martz
et al., 2014). Inhibitors of the MAPK pathway, including MEK,
have also been developed and are commonly used for the
treatment of NRAS mutant melanomas (Johnson and Puza-
nov, 2015). The emergence of immune checkpoint therapy
has resulted in unprecedented clinical success and offered
new therapeutic modalities (Colli et al., 2017; Eggermont
et al., 2018; Ribas et al., 2019). At present, BRAF inhibitors
(BRAFi) and MEK inhibitors (MEKi) are being tested in
several clinical trials, in combination with other therapies,
including immune checkpoint inhibitors and gut microbiota
modulators (Humphries and Daud, 2018; Matson et al.,
2018; York, 2018).
The gastrointestinal (GI) tract harbors a complex and dy-
namic population of bacteria, called gut microbiota, that are
implicated in the maintenance of health and the onset and pro-
gression of disease (Sommer and Ba¨ckhed, 2013). In these
roles, gut microbiota affect key components of host physiology
and homeostasis, including the development and function of
the immune system (Ba¨ckhed et al., 2005; Ley et al., 2008).
Changes in gut microbiota composition are linked to local
and systemic alterations that affect tumor growth, in part
through modulation of tissue remodeling, mucosal immunity,
and anti-tumor immunity (Rutkowski et al., 2015). Gut micro-
biota also influence the incidence and progression of colorectal
carcinoma (Arthur et al., 2012; Bonnet et al., 2014) and breast
and hepatocellular carcinoma (Arthur et al., 2012; Dapito
et al., 2012). The importance of gut microbiota composition in
cancer (Adolph et al., 2013) has been further demonstrated in
studies showing the ability of the microbiota to enhance re-
sponses to checkpoint inhibitors such as anti-PD-(L)1 anti-
bodies (Gopalakrishnan et al., 2018b; Haapanen et al., 1997;
Matson et al., 2018; Sivan et al., 2015) and anti-CTLA-4 anti-
bodies (Chaput et al., 2017; Ve´tizou et al., 2015). Furthermore,
bacterial commensals that were found to be more abundant in
the gut of melanoma patients responding to anti-PD-1 therapy
(Gopalakrishnan et al., 2018b; Haapanen et al., 1997; Matson
et al., 2018; Sivan et al., 2015), provided a rationale for perform-
ing fecal microbiota transplantation to non-responding
patients.
Despite their clinical efficacy, checkpoint inhibitors are
effective in only a fraction of treated patients. Human fecal
microbiota derived from therapy-responsive patients confer
treatment responsiveness when transplanted into germ-free
(GF) mice (Matson et al., 2018; Routy et al., 2018), while a
small set of phylogenetically unrelated gut microbiota species
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was suggested to promote anti-tumor phenotypes.
For example, introduction of Bacteroides thetaiotaomicron or
Bacteroides fragili to GF mice was sufficient to restore anti-
tumor responses via induction of a skewed Th1 response
(Ve´tizou et al., 2015). Our recent study demonstrated that
Bacteroides rodentium induced anti-tumor immunity in mela-
noma and colon cancer models that were subcutaneously im-
planted in syngeneic C57BL/6 mice (Li et al., 2019b). In
another study, the abundance of Akkermansia muciniphila
was associated with anti-PD-1 responsiveness in humans
and restored an anti-tumor phenotype when co-administered
with anti-PD-1 therapy to melanoma patients (Routy et al.,
2018). Administration of Bifidobacterium spp. in combination
with anti-PD-L1 agents, attenuated tumor growth and pro-
moted anti-tumor immunity in a syngeneic mouse model
(Sivan et al., 2015). Moreover, human melanoma patients
who responded to anti-CTLA-4 (ipilimumab) were found to
have gut microbiota enriched in three butyrate-producing
bacterial species (Chaput et al., 2017), and administration of
Enterococcus hirae and Barnesiella intestinihominis improved
their response to cyclophosphamide chemotherapy (Daille`re
et al., 2016). An assessment of mice treated with various
antibiotics revealed that ampicillin-treated mice retained a
simplified microbiota with a potent anti-tumor phenotype
(Tanoue et al., 2019). Isolates from these mice identified 11
strains, enriched in Bacteroides, Parabacteroides, Alistipes,
and an uncharacterized Ruminococcaceae, that increased
the abundance of CD8+ interferon-g (IFN-g)-producing cells
in the gut and potentiated anti-PD-1- and anti-CTLA-4-medi-
ated control of tumor growth. Collectively, these findings point
to the importance of gut microbiota in controlling cancer
growth and reveal the complex variety of species that can
promote anti-tumor immunity.
Previous reports indicated that the prebiotic inulin increases
the relative abundance of Bifidobacteria, Bacteroides, and
Akkermansia muciniphila in mice (Everard et al., 2013; Fehl-
baum et al., 2018; Li et al., 2019a; Singh et al., 2018). Among
these, Akkermansia muciniphila is known to reside in the
mucin layer of the GI tract, in which it consumes glycan
substrates decorating mucin proteins (muc2). Our earlier
studies identified microbiota-dependent anti-melanoma im-
munity in syngeneic Rnf5/ mice, which was conferred by
select bacterial strains that induced tumor infiltration by
T cells and dendritic cells (DCs) and inhibited melanoma
growth upon their inoculation in GF mice (Li et al., 2019b).
The prebiotics inulin and mucin have been reported to
induce Bifidobacterium spp. and Akkermansia muciniphila
(Everard et al., 2013; Fehlbaum et al., 2018; Li et al., 2019a;
Singh et al., 2018). Cultivation of fecal samples with inulin
and mucin increased the relative abundance of several
species implicated in tumor growth control in the Rnf5/
mice (Li et al., 2019b). Therefore, in this study, we investigated
the effects of inulin and porcine gastric mucin on growth of a
subcutaneously implanted tumor and its propensity to resist
targeted therapy in syngeneic mouse models. We demon-
strate the ability of these prebiotics to elicit changes in gut
microbiota composition that play a pivotal role in eliciting
effective anti-tumor immunity.
RESULTS
Prebiotic Treatment of Fecal Microbiota In Vitro
Enriches for Taxa that Promote Anti-tumor Immunity
Inulin and mucin have been shown to alter the relative abun-
dance of bacterial species that were identified as anti-tumor
immunity-promoting bacteria in Rnf5/ mice, including
Parasutterella excrementihominis, Bacteroides rodentium, and
Clostridium viride (Figures S1A and S1B). We thus tested the
effect of inulin and mucin on anaerobic cultivation of 12 fecal
samples derived from healthy human subjects. Both prebiotics
increased the relative abundance of Bacteroides spp., whereas
only mucin increased the relative abundance of Akkermansia
muciniphila in most cultures (Figure S1C). Surprisingly, inulin,
but not mucin, promoted the growth of Bifidobacteria spp. in
only two of the cultures.
Feeding of Mucin or Inulin to Wild-Type Mice Reduces
Tumor Growth and Induces Anti-tumor Immunity
Inulin is a naturally occurring fructosyl polymer with chain-termi-
nating glucosyl residues. Mucins are highly decorated with poly-
saccharides composed of various core structures similar to
those found in Lewis blood type antigens, including the sugars
galactose, fucose, sialic acid, galactosamine, glucosamine,
and mannose. To determine whether prebiotics inhibit tumor
growth, mucin (3% in drinking water) or inulin (15% w/w in
chow) were administered to wild-type (WT) C57BL/6 mice start-
ing 2 weeks before subcutaneous injection of syngeneic mela-
noma tumor cells (YUMM1.5 cells, 13 106 cells/mouse) through
the remainder of the experiment. Administration of mucin or
inulin led to attenuated melanoma tumor growth (Figure 1A). To
determine whether these changes could be attributed to anti-
tumor immunity, we analyzed tumor-infiltrating lymphocytes
(TILs) 20 days following tumor inoculation. Compared with
control mice, tumors from mucin- or inulin-treated mice were
enriched in CD45+ cells, including effector (CD44hi) CD4+ and
CD8+ T cells (e.g., IFN-g-producing CD4+ T cells), plasmacytoid
DCs, and conventional CD8a+ DCs (Figures 1B–1D). Tumor-resi-
dent DCs isolated from inulin- or mucin-treated C57BL/6 mice
expressed higher levels of major histocompatibility complex
(MHC) class I and MHC class II (Figure 1E), implying greater
stimulatory capacity, compared with the tumor-associated cells
from control mice. These data indicate that prebiotic supple-
mentation induced a shift to a proinflammatory tumor microenvi-
ronment associated with a more potent anti-tumor response.
The immunomodulatory effects of the two prebiotics were
largely overlapping, but not identical, yet had similar effects on
tumor control. Antibody-mediated depletion of CD4+ and CD8+
T cells in inulin-treated mice (Figure 1F) reduced the
suppression of tumor growth, pointing to an essential role
for CD4+ and CD8+ T cells in the inulin-promoted anti-tumor
phenotype.
Mucin and Inulin Feeding Enhances Expression of
Anti-tumor Immunoregulatory Genes in Tumors
To identify possible mechanisms for the elevated immune cell
infiltration and anti-tumor immunity in prebiotic-treated mice,
we examined tumor-xenograft samples grown in syngeneic
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mouse models for changes in the transcription of immune-asso-
ciated genes (including chemokines), inflammasome
activity, and antigen presentation. Both prebiotics increased
the expression of chemokines (CCL4 and CCL8), inflamma-
some-related genes (TLR3 and TLR7), and antigen presenta-
tion-related genes (CD40, Stat1, and ICOS) (Figure 2A), suggest-
ing a mechanism by which prebiotic supplementation enhanced
the recruitment and activation of immune cells in the tumor
microenvironment.
Independent support for the activation of T cells in prebiotic-
treatedmicewas obtained using theOVA-specificOT-I transgenic
mouse model. WT OT-I CD8+ CD45.1+ T cells were transferred to
untreated or mucin-treated WT mice harboring B16F10-OVA
melanoma tumors, and their frequency in tumor-draining and
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Figure 1. Administration of Mucin or Inulin Reduces Tumor Growth and Induces Anti-tumor Immunity
(A) Growth of YUMM1.5 tumors that were subcutaneously transplanted in syngeneic C57BL/6 mice. Mice were provided with a control diet, 3%mucin in drinking
water, or 15% inulin-supplemented chow starting 14 days before tumor inoculation (control, n = 12; mucin, n = 15; inulin, n = 15).
(B) Quantification of tumor-infiltrating total CD45+ cells and effector (CD44hi) CD4+ or CD8+ T cells from mice treated as in (A) (control, n = 9; mucin, n = 10;
inulin, n = 10).
(C) Quantification of tumor-infiltrating, IFN-g-producing CD4+ T cells from mice treated as in (A) (n = 10).
(D) Quantification of tumor-infiltrating total DCs and DC subsets in mice treated as in (A) (control, n = 9; mucin, n = 10; inulin, n = 10).
(E) MFI of MHC class I and MHC class II on tumor-infiltrating DCs in mice treated as in (A) (control, n = 9; mucin, n = 10; inulin, n = 10).
(F) Wild-type C57BL/6 mice (n = 12) were fed control or 15% inulin-supplemented chow starting 14 days before subcutaneous (s.c.) injection of YUMM1.5
melanoma cells (1 3 106). Anti-mouse Thy1.2 or control immunoglobulin G (IgG, 400 mg) were injected two times a week starting 3 days after tumor inoculation
(n = 12). Tumor volumewas assessed two times aweek. FACS analysis revealed >90%depletion of bloodCD4+ andCD8+ T cells on day 8 after tumor inoculation.
Data are representative of three independent experiments (A–E) or one experiment (F). Graphs show the mean ± SEM. *p < 0.05, **p < 0.005, ***p < 0.001,
****p < 0.0001 by two-way ANOVA with Bonferroni’s correction (A and F) or by one-way ANOVA with Bonferroni’s correction (B–E).
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non-draining lymph nodeswasmonitored. OT-I CD8+ T cells were
more abundant in the draining lymph nodes ofmucin-treatedmice
compared with control mice (Figures 2B and S2A), pointing to
either increased recruitment or increased survival of OT-1 cells in
the prebiotic-treated mice. Altogether, these results confirm that
prebiotic treatment promotes anti-tumor immunity via effects on
both innate and adaptive immune cells.
Consistent with the elevated abundance of TILs in mucin-
treated compared with control C57BL/6 mice, levels of the cyto-
kine interleukin (IL)-1a and chemokine CXCL13 were increased
in the sera of mucin-fed mice before tumor cell inoculation (Fig-
ure 2C), suggesting that the inflammation-promoting effects of
mucin were systemic. Strikingly, we found that mucin-treated
tumor-xenograft-bearing mice exhibited reduced serum levels
of IL-6, IL-1a, IL-10, IL-17A, and IL-23 compared with control
animals (Figure 2D). High serum levels of IL-6 and IL-17 were
previously associated with poor clinical outcome (Rutkowski
et al., 2015; Wang et al., 2009), whereas reduced IL-1a levels
Figure 2. Mucin and Inulin Induce Enhanced Expression of Immunoregulatory Genes in Tumors
(A) qPCR analysis of immune-related genes in subcutaneously transplanted melanoma grown in syngeneic C57BL/6 mice that received a control diet, 3%mucin
in drinking water, or 15% inulin-supplemented chow starting 14 days before tumor inoculation (n = 6).
(B) Quantification of CD45.1+ OT-I CD8+ T cells in the tumor-draining lymph nodes (TdLN) and non-draining lymph nodes (ndLN) of C57BL/6 mice (CD45.2+)
treated with or without mucin and injected with B16-OVA melanoma cells (TdLN, n = 7; ndLN, n = 8). Right dot plots show gating of CD45.1+ CD8+ cells.
(C) Serum cytokine and chemokine levels in naive WT mice treated with or without mucin (n = 10).
(D) Serum cytokines in WT mice treated with or without mucin on day 10 after tumor inoculation (n = 10).
Data are representative of three independent experiments (A and B) or one experiment (C and D). Graphs show the mean ± SEM. *p < 0.05, **p < 0.005,
***p < 0.001, ****p < 0.0001 by one-way ANOVA with Tukey’s correction (A) or by two-tailed t test or Mann-Whitney U test (B–D).
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were associated with attenuated tumor growth (Apte et al.,
2006). Lower serum levels of the chemokines CXCL1 and
CXCL13 were also found in mucin-treated mice compared with
control mice (Figure S2B), linking levels of both chemokines
and cytokines with the anti-tumor response.
Inulin and Mucin Alter Gut Microbiota
We next used 16S rRNA amplicon sequencing to profile the
fecal microbiota of WT C57BL/6 mice before and 14 days
after prebiotic feeding and 20 days after YUMM1.5 tumor
cell inoculation, with tumor cells originally obtained from
genetically engineered C57BL/6 mice harboring BrafV600E
mutation, Pten deletion, and Cdkn2a deletion. Although the
bacterial communities at baseline were heterogeneous and
generally not well clustered (Figures 3A and 3B), prebiotic
feeding resulted in the formation of more highly related
communities that were distinct from those in control mice.
Furthermore, the bacterial communities underwent additional
restructuring following tumor cell inoculation. These data are
consistent with recent observations that distal tumor growth
results in a reconfiguration of gut microbiota (Li et al.,
2019b). Individual phylotype groups (two or more highly
related, but not identical, 16S sequences of strains approxi-
mating a species) that were altered in the microbiota of
Figure 3. Mucin and Inulin Modulate the Composition and Diversity of Gut Microbiota
(A and B) Principal-component analysis of all taxa enumerated in fecal microbiota of control and mucin-treated (A) or inulin-treated (B) C57BL/6 mice, examined
before prebiotic treatment, before subcutaneous injection of syngeneic YUMM1.5 tumor cells, and before tumor collection (control, n = 12; mucin, n = 15; inulin,
n = 15).
(C) Time course of the relative abundance of the six taxa enriched in inulin-treated mice that negatively correlate with YUMM1.5 tumor size (control, n = 12; inulin,
n = 15). Time points are before inulin treatment, before tumor injection, and before tumor collection.
Data are representative of two independent experiments.
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control and prebiotic-treated mice were identified but were
not further assessed. Thus, only phylotypes that were
associated with a specific prebiotic treatment were further
studied.
Sequencing of the amplified 16S V3-V4 region followed by
computational analysis led to the identification of increased
relative abundance of 17 phylotype groups in inulin-treated
mice and 2 phylotype groups in the mucin-treated mice that
were not present in control mice (Table S1). Inulin increased
the relative abundance of taxa that were phylogenetically
coherent, 66% of which mapped most closely to members
of Clostridium cluster XIVa, primarily Clostridium populeti-
and Clostridium saccharolyticum-related taxa (Table S1).
Although this cluster consists of numerous butyrate pro-
ducers, the phylogenetic distance of the phylotypes profiled
here makes the butyrate-producing potential of these taxa
uncertain. Among the phylotypes that displayed increased
relative abundance following inulin treatment, six were
negatively correlated with tumor size (Figure 3C). Mucin also
predominantly enriched taxa with similarity to members of
Clostridium cluster XIVa (Table S1); however, none of the
phylotypes induced by mucin were negatively correlated
with tumor size. These findings suggest that inulin and mucin
drive distinct changes in gut microbiota, both of which are
capable of inducing anti-tumor immunity.
Inulin Attenuates Colon Cancer Growth
We next assessed whether mucin or inulin supplementation
affects the growth of tumor types other than melanoma. Using
the same protocol (prebiotic feeding starting 2 weeks before
tumor inoculation), we found that inulin, but not mucin, atten-
uated the growth of subcutaneously transplanted MC-38
colon cancer tumors in syngeneic C57BL/6 mice (Figure 4A)
and enhanced the anti-tumor immune response, as reflected
by increased MHC class I and MHC class II expression on
DCs (Figure 4B). No differences in the abundance of CD4+
or CD8+ T cells, total CD45+ cells, DCs, or DC subsets or
the production of cytokines were observed in tumors from
mucin- or inulin-treated mice (Figure S3). Although both mucin
and inulin induced anti-tumor immunity that limited the growth
of melanoma tumors, only inulin was able to attenuate colon
cancer growth. Thus, the differences in taxa induced by these
prebiotics may account for their distinct effects on control of
select tumor types.
Specific Microbiota Are Associated with Control of
Colon Cancer Growth and Anti-tumor Immunity
Analysis of fecal microbiota fromMC-38 tumor-bearing inulin- or
mucin-treated mice indicated that both prebiotics increased the
relative abundance of a similar number of phylotype groups
(25 inulin and 21 mucin), of which 7 were common to both prebi-
otics (Table S2). More than 68%of the phylotype groups induced
by inulin mapped to Clostridium cluster XIVa, compared with
33% induced by mucin. Additional analysis demonstrated that
the relative abundance of six inulin-specific phylotypes was
inversely correlated with MC-38 tumor size (Figure 4C), whereas
no relationship with tumor size was detected for the phylotype
groups induced by mucin.
Combination Treatment with Inulin Overcomes
Melanoma Resistance to MEKi
We next determined whether prebiotic supplementation influ-
enced the efficacy of MEKi treatment by examining growth of
the N-RAS mutant mouse melanoma cell line MaN-RAS that
was obtained from genetically engineered N-Ras melanoma
grown in C57BL/6 mice. Syngeneic mice (C57BL/6) were subcu-
taneously inoculated with tumor cells 2 weeks after the initiation
of feeding with inulin or mucin with or without MEKi. In the
absence of MEKi, inulin, but not mucin, modestly controlled tu-
mor growth (Figure 5A). However, co-administration of MEKi
with inulin had an additive effect on tumor growth control, and
the emergence of MEKi resistance was delayed compared
with MEKi alone (Figure 5A), implying that MEKi resistance
may be partially overcome by this prebiotic. Consistent
with these findings, tumors from mice treated with inulin+MEKi
contained elevated numbers of total CD45+ cells, CD4+ and
CD8+ T cells, pDCs, andmDCs, and the DCs expressed elevated
levels of MHC class I compared with mice treated with MEKi
alone (Figures 5B and 5C). However, no differences in T cell-
mediated cytokine production were detected in tumors from
inulin+MEKi-treated mice (Figure S4A).
Inulin-Induced Alterations in Gut Microbiota Control
NRAS Mutant Melanoma Tumor Growth and MEKi
Resistance
Inulin and mucin treatment before MEKi injection increased the
relative abundance of 39 and 23 phylotype groups, respectively
(Figures 5D, S4B, and S4C), and the abundance of these groups
was negatively correlated with tumor size (Figures S4B and
S4C). Both inulin and mucin primarily increased the relative
abundance of taxa mapping in or near Clostridium cluster XIVa
(Figures 5D and 5E). Inulin specifically induced six phylotypes
related to Bacteroides spp. (primarily Bacteroides acidifaciens),
three phylotypes related to Barnesiella spp., and a group related
to Parasutterella excrementihominis, the latter of which was not
detected following mucin treatment. Inulin also increased the
relative abundance of three phylotype groups related to Bifido-
bacterium spp., whereas only one group was induced by mucin.
The genomes of Bacteroides, Bifidobacterium, and Barnesiella
spp. encode numerous glycosyl hydrolase activities (http://
www.cazy.org/) that support cross-feeding interactions with
sugar-fermenting bacteria, particularly Clostridiales spp.
Mice treated with doses of MEKi alone that effectively
controlled subcutaneously implanted MaN-RAS1 tumor growth
in syngeneic C57BL/6 mice showed enrichment of 14 phylotype
groups in the gutmicrobiota, none of which negatively correlated
with tumor size (Table S3). Analysis of taxa in tumor-bearingmice
fed inulin identified eight phylotype groups enriched in Actino-
bacteria, Bifidobacterium longum, and two Olsenella spp. (Table
S3). Only one phylotype group mapping distantly to Clostridium
cellobioparum was negatively correlated with tumor size. Mucin
treatment alone resulted in an increase in the relative abundance
of 56 phylotype groups featuring diversity of taxa, including
Bacteroides,Parabacteroides,Olsenella, andClostridium. Mucin
uniquely increased the relative abundance of five Lactobacillus
spp., all of which were positively correlated with tumor size,
albeit not to the level of statistical significance. Mucin feeding
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may thus induce an imbalance between enrichment of phylo-
types that correlated positively versus negatively with tumor
size, resulting in a failure to control tumor growth (Table S3).
MEKi co-administration altered the relative abundance of 21
phylotype groups (5 increased) in inulin-treated mice and of 15
phylotype groups (6 increased) inmucin-treatedmice at sacrifice
(Table S3). Analysis of the phylotypes in inulin+MEKi-treated
mice compared with inulin-treated mice revealed four groups
that negatively correlated with tumor size, based on relative
abundance at sacrifice (Figure 5F). Of these, Akkermansia
muciniphilawas robustly enriched, together with Actinobacteria,
Bifidobacterium longum, Olsenella profusa, and Parvibacter
caecicola. Akkermansia muciniphila has previously been
demonstrated to possess anti-tumor properties (Routy et al.,
2018). Because Akkermansia muciniphila was also induced in
mucin+MEKi-treated mice, enrichment of this phylotype may
be insufficient to control MaN-RAS tumor growth. Rather,
interactions between other inulin-induced taxa may be
required for Akkermansia muciniphila to promote the anti-tumor
phenotype. The four phylotype groups that were enriched in
Figure 4. Inulin Controls Colon Cancer Growth and Induces Anti-tumor Immunity
(A) Growth of MC-38 mouse colorectal cancer cells (1 3 106) injected subcutaneously into syngeneic C57BL/6 mice that received control diet, 3% mucin in
drinking water, or 15% inulin-supplemented chow starting 14 days before tumor inoculation (control, n = 9; mucin, n = 15; inulin, n = 15).
(B) MFI of MHC class II and MHC class I in MC-38 tumor-infiltrating DCs (n = 8).
(C) Boxplot of the relative abundance of the taxa enriched in inulin-treated mice and positively correlated with tumor size (n = 10).
Data are representative of two independent experiments. Graphs show the mean ± SEM. *p < 0.05, **p < 0.005, ***p < 0.001, ****p < 0.0001 by one-way ANOVA
with Bonferroni’s correction (B) or by two-way ANOVA with Tukey’s correction (A).
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Figure 5. Inulin Supplementation Overcomes Melanoma Resistance to MEKi
(A) Growth of NRASQ61K mouse melanoma cells (1 3 106) (control, n = 11; mucin, n = 9; inulin, n = 9; MEKi, n = 10; MEKi+mucin, n = 8; MEKi+inulin, n = 10) that
were subcutaneously transplanted in syngeneic C57BL/6 mice that received control diet, 3%mucin in drinking water, or 15% inulin-supplemented chow starting
14 days before tumor inoculation. When tumors reached a volume of 10–20 mm2, mice were administered MEKi (PD325901, 10 mg/kg) once daily by gavage.
Tumor volume was assessed every 4 days.
(B) Number of tumor-infiltrating effector (CD44hi) CD4+ and CD8+ T cells and total CD45+ cells per tumor weight (in grams) in mice treated as in (A) (MEKi, n = 7;
MEKi+mucin, n = 8; MEKi+inulin, n = 8).
(C) Number of tumor-infiltrating DCs and DC subsets per tumor weight (in grams) and expression of MHC class I on DCs in mice treated as in (A) (MEKi, n = 8;
MEKi+mucin, n = 7; MEKi+inulin, n = 8).
(D) Pie chart of taxa enriched in inulin-treated mice and negatively correlated with MaN-RAS tumor size (n = 10).
(E) Pie chart of taxa enriched in mucin-treated mice microbiota that negatively correlate with MaN-RAS tumor size (n = 10).
(legend continued on next page)
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mucin+MEKi-treated mice compared with mucin-treated mice,
and that negatively correlated with tumor size, may be involved
in mucin-promoted control of tumor growth (Figure 5G).
Meta-analysis of Anti-tumor Microbiota
Studies of microbiota-mediated control of tumor growth have
largely focused on a single or small group of bacterial species
and/or species that are over-represented in mice or humans
and are positively associated with control of tumor growth.
However, in the present study, we detected negative correla-
tions between tumor size and the abundance of multiple phylo-
genetic clades (Figure 6), which has been difficult to reconcile
with earlier studies. Some bacterial strains identified here have
not previously been described to be associated with anti-tumor
immunity. In addition to Bifidobacteria, Bacteroides, Barnesiella,
and Parabacteroides (Daille`re et al., 2016; Matson et al., 2018;
Sivan et al., 2015; Tanoue et al., 2019; Ve´tizou et al., 2015), which
have been implicated in anti-tumor responses, we identified
Olsenella, Prevotellamassilia, and Culturomica as additional
taxa whose abundance correlates with tumor size. Six members
of the Firmicutes phylum, including taxa mapping in or near
Clostridium cluster XIVa, were also associated with tumor
growth inhibition (Figure 6).
Short-Chain Fatty Acids Are Not Sufficient to Attenuate
Tumor Growth
Among the taxa enriched in gut microbiota of prebiotic-fed mice
that control tumor growth are many that mapped in or near Clos-
tridium cluster XIVa, which includes butyrate-producing species.
We therefore next tested the effect on tumor growth of individual
or combinations of the short-chain fatty acids (SCFAs) butyrate,
propionate, and acetate (150 mM alone or 50 mM each in com-
bination) administered in the drinking water starting 2 weeks
before melanoma cell injection and for the duration of the exper-
iment thereafter. None of the SCFAs, alone or in combination,
reduced the tumor burden (Figure S5A), suggesting that produc-
tion of SCFAs alone is insufficient to affect tumor growth.
Mucin-Induced Tumor Control Depends on Gut
Microbiota
To verify the dependency of prebiotic-induced tumor control on
gut microbiota, a minimal microbiota (altered Schaedler flora
[ASF]) was allowed to colonize GF C3H/HeN mice for 2 weeks
to induce immune maturation, and then the mice were initiated
on mucin treatment for 2 weeks before injection of subcutane-
ously transplanted N-Ras mutant SW1 tumor cells. In these
mice, mucin treatment failed to attenuate SW1 tumor growth
(Figure S5B), indicating that mucin-promoted tumor growth con-
trol depends on specific gut microbiota. These observations are
consistent with our previous demonstration that transfer of feces
from Rnf5/mice, which harbor microbiota that can limit tumor
growth, to WT GF mice elicited an effective anti-melanoma
response (Li et al., 2019b).
Mucin and Inulin Treatment Leads to Activation of DCs
and T Cells
To further explore the mechanism of action of mucin and inulin on
the anti-tumor immune response, we treated murine bone
marrow-derived DCs (BMDCs) for 24 h in vitrowithmucin or inulin
(0.05 or 0.5 mg/mL). As shown in Figure S5C, expression of the
DC activation markers CD40 and CD80, as well as MHC class I
and MHC class II, was increased by mucin treatment, but not
inulin treatment. In contrast, in vitro treatment of CD8+ T cells iso-
lated from the spleens of C57BL/6 mice revealed that whereas
mucin had a limited effect on T cell activation (Figure S5D), inulin
treatment increased the production of cytokines, chemokines,
and the cytotoxic effector protein granzymeB (Figure S5D). These
results suggest that inulin and mucin differentially affect the
expression of genes involved in activation of antigen-presenting
and/or effector functions of DCs and T cells. Given that mucin
failed to elicit anti-tumor immunity and tumor growth inhibition
in GF mice, we speculate that the effects of mucin and inulin
detected in vitro would likely be secondary to the effects of
prebiotics on the microbiota in vivo (Figure S5B).
Mucin and Inulin Promote Proinflammatory Gene
Expression in Intestinal Epithelial Cells In Vivo
We next determined the effect of mucin and inulin on gene
expression by intestinal epithelial cells (IECs), which have been
implicated in the activation of DCs and T cells in vivo (Wang
et al., 2003). After treatment of WT C57BL/6 with inulin or mucin
for 2 weeks, IECs were isolated from the small intestine andwere
examined for expression of immune-related cytokines and che-
mokines. IECs from inulin- or mucin-treated mice exhibited
enhanced expression of select genes; thus, although tumor ne-
crosis factor alpha (TNF-a) mRNA levels were elevated in IECs
from mucin-treated mice, NOD2, IL-6, and CXCL2 mRNA were
increased in IECs from inulin-treated mice (Figure S5E). These
findings suggest that inulin and mucin differentially enhance
the transcription of key immune-activating cytokines and che-
mokines in IECs, providing a potential mechanism by which
alterations of the gut microbiota may elicit anti-tumor immunity.
Prebiotic TherapyDoesNotAugment theEfficacyofAnti-
PD-1 Immune Checkpoint Therapy of Cold Melanomas
We next asked whether prebiotic treatment can enhance the
efficacy of anti-PD-1 antibody, a commonly used immune
checkpoint therapy. YUMM1.5, the BRAF mutant mouse mela-
noma cell line, is considered a cold tumor, that is, poorly respon-
sive to immune checkpoint therapy (Haanen, 2017; Meeth et al.,
2016). Administration of anti-PD-1 or the prebiotics reduced the
growth of YUMM1.5 tumors in C57BL/6 mice. However, combi-
nation treatment with anti-PD-1 plus either inulin ormucin did not
further attenuate tumor growth (Figures 7A and 7B), implying that
anti-PD-1 and prebiotic therapy may elicit similar or overlapping
changes in the immune system.
(F) Relative abundance of taxa enriched in inulin+MEKi-treated mice and negatively correlated with MaN-RAS tumor size (n = 10).
(G) Relative abundance of taxa enriched in mucin+MEKi-treated mice and negatively correlated with MaN-RAS tumor size (n = 10).
Data are representative of two independent experiments. Graphs show the mean ± SEM. *p < 0.05, **p < 0.005, ***p < 0.001, ****p < 0.0001 by one-way ANOVA
with Tukey’s correction (B and C) or by two-way ANOVA with Bonferroni’s correction (A).
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Mucin and Inulin Effects on Melanoma Growth Are
Context Dependent
To determine whether mucin and inulin in combination have
additive or synergistic effects on melanoma growth, we em-
ployed two models. In the first, the growth of syngeneic SW1
NRAS mutant melanoma tumors that were subcutaneously
transplanted in the syngeneic C3H/HeOuJ mice was attenuated
by mucin treatment alone, a response that was enhanced by co-
administration of mucin and inulin (Figure 7C). In contrast,
growth of YUMM1.5 BRAF mutant melanoma tumors that were
subcutaneously transplanted in the syngeneic C57BL/6 mice
was reduced by treatment with either mucin or inulin alone, but
they did not have an additive effect (Figure S6). These findings
suggest that tumor genotypes and/or mouse strains affect the
ability of prebiotics to attenuate tumor growth, further illustrating
the complexity of the mechanisms by which gut microbiota
impacts the anti-tumor phenotype.
DISCUSSION
In this study, we have demonstrated, using subcutaneously im-
planted tumors, that inulin and mucin induce anti-tumor immu-
nity and concomitantly control tumor growth in syngeneicmouse
models. The prebiotic effects depended on changes in the
composition of gut microbiota, as illustrated by the failure of
mucin to induce anti-tumor immunity in gnotobiotic mice
harboring a minimal ASF community. In turn, changes in gut
microbiota resulted in enhanced expression of select chemo-
Figure 6. A Cladogram Representation of
Taxa Enriched in Fecal Microbiota of Mice
Administered Mucin or Inulin
Cladogram representation of taxa enriched in fecal
microbiota of mice (control, n = 12; mucin, n = 15;
inulin, n = 15) administered mucin (red) or inulin
(blue). Data are representative of two independent
experiments.
kines and cytokines in IECs, which have
known roles in the activation of DCs and
T cells (Belkaid and Hand, 2014; Chistiakov
et al., 2015). As a result, the growth of
melanoma and/or colon cancer was atten-
uated, accompanied by increased infiltra-
tion of effector T cells and DCs and
increased expression of immune-related
genes, including chemokines and Toll-like
receptor (TLRs). Notably, our studies
were limited to subcutaneously implanted
melanoma or colon cancer cell lines in
two syngeneic mouse strains (C57BL/6
and C3H) to capture the inherent immune
response. Thus, our studies did not
address the complex nature of human
tumors, which would be achieved using
patient-derived xenografts that lack intact
immune response unless carried out in hu-
manized mouse models, and they did not
examine the effect of the prebiotics studied
here in genetically engineered mouse
models, which could have also allowed monitoring of the effect
of these prebiotics at different phases of tumor evolution and
in the proper microenvironment. Heterogenous phenotypes, of
both tumors and hosts, are likely to best represent the heteroge-
neity found in man, for which corresponding models are urgently
needed.
We found that both inulin and mucin effectively limited the
growth of melanoma cells, but they elicited distinct phenotypes
that are likely to stem from their differential effects on gut micro-
biota. For example, growth of KRASmutant MC-38 colon cancer
cells was inhibited by inulin, but not by mucin. In addition, inulin
combined with MEKi, but not mucin, was able to attenuate the
MEKi resistance of NRAS melanoma. These data suggest that
mucin and inulin elicit distinct changes in gut microbiota, which
then elicit anti-tumor immunity via different mechanisms. Our re-
sults are consistent with earlier findings that inulin can inhibit tu-
mor growth (Mauro et al., 2013; Taper and Roberfroid, 1999),
although the underlying mechanism of action remained largely
unexplored.
Inulin andmucin shared a common ability to promote substan-
tial alterations in the composition of fecal microbiota, leading to
increases in the relative abundance of multiple bacterial phylo-
types. We observed a negative correlation between the tumor
size and a subset of these phylotypes, many of which have
been reported to have anti-tumor potential in independent
studies. Among those are Bifidobacterium (Matson et al., 2018;
Sivan et al., 2015), Bacteroides (Li et al., 2019b; Ve´tizou et al.,
2015), Parabacteroides (Daille`re et al., 2016; Li et al., 2019b),
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Akkermansia muciniphila (Routy et al., 2018), and Barnesiella
(Daille`re et al., 2016). These taxa were enriched following prebi-
otic feeding and MEKi treatment, pointing to their possible
role in mediating tumor control. We previously observed
elevated expression and post-translational modification of
mucin in Rnf5/ mice, which exhibit strong anti-tumor immu-
nity, although the change in mucin expression was not accom-
panied by alterations in mucus thickness or intestinal leakiness
(Li et al., 2019b; data not shown). Thus, modification of mucin
may be one facet of crosstalk between the gut microbiota and
the immune system that contributes to the anti-tumor
phenotype.
Among the phylotypes induced by inulin and mucin are taxa in
the butyrate-producing Clostridium cluster XIVa. This result is
consistent with an earlier report demonstrating that over-repre-
sentation of three butyrate-producing taxa was strongly associ-
ated with responsiveness to ipilimumab in human melanoma
patients (Chaput et al., 2017). However, we found that butyrate,
propionate, and acetate, alone or in combination, had no
effect on melanoma growth, suggesting that production of other
SCFAs or microbial products may mediate this microbiota-
driven anti-tumor response.
Increasing attention is being paid to the effects of MEKi, which
target a signaling pathway often deregulated in tumors, on im-
mune system components (Sanlorenzo et al., 2018; Yue et al.,
2018). MEKi has been shown to impede the growth of tumors
in mice while concomitantly promoting the effector phenotype
and longevity of tumor-infiltrating CD8+ T cells (Ebert et al.,
2016). Furthermore, MEKi can promote tumor immunogenicity
in preclinical models of triple-negative breast cancer, in which
MEKi in combination with either anti-4-1BB or anti-OX-40
agonist antibodies resulted in superior therapeutic efficacy
(Dushyanthen et al., 2017). MEKi is also capable of promoting
the maturation of DCs, as reflected by enhanced antigen uptake,
processing, and cross-presentation to T cells (Vella et al., 2014).
Despite effective tumor inhibition by MEKi, resistance to these
inhibitors invariably occurs (Brighton et al., 2018; Fedele et al.,
2018). Here, we demonstrated that co-administration of inulin
reduces the resistance of melanoma to MEKi, pointing to the
possible consideration of prebiotics as a means to limit therapy
resistance, which remains a crucial unmet clinical need.
Several lines of evidence support the ability of microbiota to
enhance the effectiveness of chemotherapy, radiotherapy, and
immunotherapy (Alexander et al., 2017; Iida et al., 2013; Roy
and Trinchieri, 2017). However, more recent studies have
shown that antibiotic treatment or select enrichment of gut mi-
crobiota taxa can also limit the effectiveness of immune check-
point therapy (Gopalakrishnan et al., 2018a, 2018b; Pitt et al.,
2016). Thus, our finding that inulin and mucin are as effective
as anti-PD-1 immune checkpoint therapy in limiting cold mela-
noma growth suggests that these prebiotics do not impede but
possibly affect the same pathways as anti-PD-1 therapy.
Combination treatment with inulin and mucin had an additive
effect on the growth of NRAS mutant SW1 melanoma in C3H/
HeOuJ mice, but not on the growth of YUMM1.5 BRAF mutant
melanoma in C57BL/6 mice, further illustrating that the effec-
tive cooperation between prebiotics depends on both tumor
and genetic background.
Collectively, the results of this study advances our under-
standing of tumor growth control by gut microbiota, demon-
strating that taxa from multiple unrelated phylogenetic groups
share the capacity to induce anti-tumor immunity. It is expected
that refinement of the specific bacterial strains and metabolites
that mediate these phenotypes will not only advance our under-
standing of the phenomenon but also facilitate the development
of therapeutic modalities that could be tested across species.
Figure 7. Combination Therapy with Prebi-
otics andAnti-PD-1Modulates TumorGrowth
in a Context-Dependent Manner
(A) Growth of YUMM1.5 tumors that were subcuta-
neously transplanted in syngeneic C57BL/6 mice
that were fed control chow or chow supplemented
with 15% inulin starting 14 days before tumor inoc-
ulation (control, n = 7; inulin, n = 7; PD-1, n = 10; PD-
1+inulin, n = 9). Mice were injected with control IgG
or anti-PD-1 blocking antibody on days 7, 10, 13,
and 16 after tumor inoculation.
(B) Growth of YUMM1.5 tumors in C57BL/6 mice
that received 0% or 3% mucin in drinking water
starting 14 days before tumor inoculation (control,
n = 7; mucin, n = 7; PD-1, n = 10; PD-1+mucin, n = 9).
Mice were injected with antibodies as described
in (A).
(C) Growth of SW1 mouse melanoma cells in C3H/
HeOuJ mice that received a control diet, 3% mucin
in drinking water, or 15% inulin-supplemented chow
starting 14 days before tumor inoculation (control,
n = 8; mucin, n = 8; inulin, n = 7; mucin+inulin, n = 9).
Data are representative of two independent experi-
ments. Graphs show the mean ± SEM. *p < 0.05,
**p < 0.005, ***p < 0.001, ****p < 0.0001 by two-way
ANOVA with Bonferroni’s correction.
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Antibodies
Purified anti-mouse CD16/32 BioLegend Cat#101302; clone 93; RRID: AB_312800
PerCP anti-mouse CD45.2 BioLegend Cat# 109826; clone 104; RRID: AB_893349
Pacific Blue anti-mouse CD8a BioLegend Cat# 100725; clone 53–6.7; RRID: AB_493425
Brilliant Violet 605 anti-mouse CD4 BioLegend Cat# 100451; clone GK1.5; RRID:AB_2564591
FITC anti-mouse CD25 BioLegend Cat# 101908; clone 3C7; RRID: AB_961210
APC/Cy7 anti-mouse/human CD44 BioLegend Cat# 103028; clone IM7; RRID: AB_830785
PE/Cy7 anti-mouse TNF-a BioLegend Cat# 506324; clone MP6-XT22; RRID: AB_2204356
APC anti-mouse IFN-g BioLegend Cat# 505810; clone XMG1.2; RRID: AB_315403
APC anti-mouse CD11c BioLegend Cat# 117310; clone N418; RRID: AB_313778
APC anti-mouse CD103 BioLegend Cat# 121414; clone 2E7; RRID: AB_1227503
FITC anti-mouse H-2Kb BioLegend Cat# 116506; clone AF6–88.5; RRID: AB_313733
Pacific Blue anti-mouse I-A/I-E BioLegend Cat# 107620; clone M5/114.15.2; RRID: AB_493527
FITC anti-mouse CD45.1 BioLegend Cat# 110706; clone A20; RRID: AB_313495
APC/Cy7 anti-mouse/human CD11b BioLegend Cat# 101225; clone M1/70; RRID: AB_830641
PE anti-mouse CD317 (BST2, PDCA-1) BioLegend Cat#127104; clone129C1; RRID: AB_1953283
FITC anti-mouse/human IL-2 eBioscience Cat# 11-7021-41; clone JES6-5H4; RRID:
AB_10734043
FITC anti-mouse/human MHC Class I eBioscience Cat# 11-5958-82; clone AF6-88.5.5.3; RRID:
AB_11149502
PE/Cy7 anti-mouse/human CD45R/B220 BioLegend Cat# 103222; clone RA3-6B2; RRID: AB_313005
GoInVivo Purified anti-mouse CD279 (PD-1) BioLegend Cat# 114112; clone RMP1-14; RRID: AB_2566090
GoInVivo Purified Rat IgG2a, k Isotype Ctrl BioLegend Cat#400560; clone RTK2758
InVivoMAb anti-mouse Thy1.2 (CD90.2) BioXCell Cat# BE0066; clone 30H12; AB_1107682
Bacterial and Virus Strains
ASF (Li et al., 2018) N/A
Chemicals, Peptides, and Recombinant Proteins
GM-CSF BioLegend Cat# 576306
CFSE (carboxyfluorescein succinimidyl easter) Thermo Fisher Scientific Cat# C34554
Collagenase D Roche Cat #11088882001
DNase Sigma Cat #DN25-1G
Brefeldin A Sigma Cat# B7651-5MG
Phorbol 12-myristate 13-acetate Sigma Cat# P8139-1MG
Ionomycin calcium salt Sigma Cat# 3909-1ML
Mucin Lee Biosolutions Cat# 435-10
Dulbecco’s modified Eagle’s medium (DMEM) Corning Cat# 10-013-CV
Fetal bovine serum (FBS) Gemini Bioproducts Cat#900-208
Penicillin (100 units/mL) and Streptomycin
(100 ug/mL)
Corning Cat#30-002-CI
Trypsin-EDTA (0.25%), phenol red Fisher Scientific Cat#25200056
DPBS without Mg2+ and Ca2+ Corning Cat#21-031-CV
HBSS without Mg2+ and Ca2+ Corning Cat#21021152
RBC lysis buffer Sigma Cat#R7757
HEPES Buffer Corning Cat#25-060-CI
2-mercaptoethanol Sigma Cat#133051
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Critical Commercial Assays
RNeasy Plus Mini Kit QIAGEN Cat#74134
LEGENDplex mouse inflammation panel BioLegend Cat#740446
LEGENDplex mouse proinflammatory chemokine
panel
BioLegend Cat#740451
RNeasy Fibrous Tissue Mini kit QIAGEN Cat#74704
High Capacity Reverse Transcriptase kits Invitrogen Cat#4368814
SYBR Green RT-PCR kits Invitrogen Cat#4385610
BD Cytofix/Cytoperm BD Biosciences Cat#554714
QIAquick 96-PCR Cleanup kit QIAGEN Cat#28181
QIAamp Fast DNA Stool Mini Kit QIAGEN Cat#51604
Deposited Data
Bacterial 16 s sequence This paper The approach used to map microbiota taxa is detailed
at: http://github.com/taolonglab/himap; BioRxiv 565572.
The microbiome sequence data have been deposited in
the NCI BioProject: PRJNA593851 https://
www.ncbi.nlm.nih.gov/bioproject/PRJNA593851
Raw data This paper The raw data were deposited to Mendeley
https://data.mendeley.com/datasets/zrjr39f7
mb/draft?a=28ed04b4-6d90-4eec-be59-c42e05589ade.
Experimental Models: Cell Lines
Mouse: YUMM1.5 Gift from Marcus Bosenberg
(Meeth et al., 2016)
N/A
Mouse: MC-38 Gift from Michael Karin
(Li et al., 2019b)
N/A
Mouse: MaN-RASQ61K Gift from Lionel Larue
(Petit et al., 2019)
N/A
Mouse: SW1 Gift from Margaret Kripke
(Bhoumik et al., 2002)
N/A
Mouse: B16-OVA Gift from Linda Bradley
(Li et al., 2019b)
N/A
Experimental Models: Organisms/Strains
Mouse: C57BL/6 Sanford Burnham Prebys
Medical Discovery Institute
N/A
Mouse: CD45.1 (B6.SJLB6.SJL-Ptprca Pepcb/BoyJ) The Jackson Laboratory Stock No: 002014
Mouse: C3H/HeOuJ The Jackson Laboratory Stock No: 000635
Mouse: EX-germ-free ASF-bearing C3H/HeN University of Nebraska-
Lincoln (UNL)
N/A
Oligonucleotides
qPCR primer sequences, See Table S4 This paper N/A
V3-V4 Forward primer: TCGTCGGCAGCGTCAGAT
GTGTATAAGAGACAGCCTACGGGNGGCWGCAG
This paper N/A
V3-V4 Reverse primer: GTCTCGTGGGCTCGGAG
ATGTGTATAAGAGACAG GACTACHVGGGTATCT
AATCC
This paper N/A
Software and Algorithms
GraphPad Prism 6 and 7 Graphpad Software N/A
FlowJo v10.1 and v9.9 Treestar N/A
FACSDiva Software BD N/A
Algorithms HiMAP This paper N/A
LEGENDplexTM BioLegend N/A
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for reagents should be directed to and will be fulfilled by the Lead contact, Ze’ev Ronai, at zeev@
ronailab.net. All reagents generated in this study are available from the LeadContact with a completedMaterials Transfer Agreement.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals and tumor model
All experimental animal procedures were approved by the Institutional Animal Care and Use Committee of Sanford Burnham Pre-
bys Medical Discovery Institute (SBP: approval #13-130, 16-028, and 17-001) and complied with all relevant ethical regulations for
animal testing and research. C57BL/6 mice were obtained from SBP. OT-I mice were obtained from SBP and crossed to CD45.1+
B6.SJLB6.SJL-Ptprca Pepcb/BoyJ mice (Jackson Laboratories). C3H/HeOuJ mice were purchased from Jackson Laboratories.
Male 6–8-week-old mice were used for all experiments. GF ASF-bearing C3H/HeN mice were bred and maintained at the Univer-
sity of Nebraska-Lincoln (UNL) Gnotobiotic Mouse Facility under gnotobiotic conditions in flexible film isolators. Experiments
involving GF and gnotobiotic mice were approved by the Institutional Animal Care and Use Committee at UNL (protocol
#1534). All mice were fed an autoclaved chow diet ad libitum (LabDiet 5K67, Purina Foods). GF status was routinely checked
as previously described (Gomes-Neto et al., 2017). Briefly, fresh feces were collected and analyzed by bacterial 16S rRNA
gene-specific PCR (30 cycles, universal bacteria primers 8F and 1391R) in combination with aerobic and anaerobic culture of
feces in Brain Heart Infusion, Wilkins–Chalgren, and Yeast Mold broths, and on Tryptic Soy Agar plates (all media from Difco Bec-
ton Dickinson) at 37C for 7 days. ASF colonization status was verified by qPCR analysis of fecal samples as previously described
(Li et al., 2019b). Briefly, genomic DNA was extracted from fecal samples and ASF bacteria were quantified by qPCR with species-
specific primers.
For tumor growth experiments, mice were injected subcutaneously (s.c.) with 13 106 tumor cells. Tumor size wasmeasured twice
a week for calculation of tumor volume. Tumors were weighed at the time of excision. Mouse selection for experiments was not
formally randomized or blinded.
Cell lines
BrafV600E/+;Pten/;Cdkn2a/ mouse melanoma cell line YUMM1.5 (Meeth et al., 2016), MC-38 cells ((Hampton et al., 2000); pro-
vided by M Karin, UCSD), MaN-RASQ61K mouse melanoma cells ((Petit et al., 2019); Provided by Lionel Larue, CNRS) SW1 mouse
melanoma cells ((Bhoumik et al., 2002); provided by M Kripke, MDACC) B16-OVA ((Bellone et al., 2000); Provided by L Bradley SBP).
Cell lines were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum (FBS) and antibiotics.
All cell lines were free of mycoplasma and were authenticated by SBP genomic core service.
Bacterial strains and anaerobic fecal cultures
ASF (Altered Schaedler Flora) consisted of the following eight isolates: ASF 356, Clostridium sp.; ASF 360, Lactobacillus intestinalis;
ASF 361, Lactobacillus murinus; ASF 457,Mucispirillum schaedleri; ASF 492, Eubacterium plexicaudatum; ASF 500, Pseudoflavoni-
fractor sp.; ASF 502,Clostridium sp.; and ASF 519,Parabacteroides goldsteinii. Stool collected from 12 healthy vegetarian volunteers
orWTmice (approximately 106 cells) were inoculated into chemically definedmedium (CDM) alone or supplementedwith 1% inulin or
1%porcine gastric mucin in Hungate tubes. Anaerobic cultures (9%H2, 81%N2) were grown statically for 3–4 days at 3
C to approx-
imate saturation.
METHOD DETAILS
Chemically defined medium (CDM)
CDM contained 50 mM HEPES, 2.2 mM KH2PO4, 10 mM Na2HPO4, 60 mM NaHCO3; 4 mM of each amino acid except leucine
(15 mM); 10 mL ATCC Trace Mineral Supplement; nucleoside bases (100 mg/L) inosine, xanthine, adenine, guanine, cytosine, thymi-
dine, and uracil (400 mg/L); choline (100 mg/L), ascorbic acid (500 mg/L), lipoic acid (2 mg/L), hemin (1.2 mg/L), and myo-inositol
(400 mg/L). Resazurin (1 mg/L) was added to visually monitor dissolved oxygen. The pH was adjusted to 7.4.
Continued
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Other
100 um cell strainer Thermo Fisher Cat# 22363549
Purified Diet, AIN-93M, ENVIGO TD. 94048,
Modified AIN-93M, Diet w 15% inulin, ENVIGO TD. 160256
Chow diet ad libitum (Purina Foods) LabDiet Form: 5K67
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Bacterial DNA extraction and 16S library preparation
Gut microbiota in the mouse reach a stable homeostatic state at about 8 weeks of age (Laukens et al., 2016). Fecal pellets frommice
R 8 weeks of age were frozen on dry ice and stored at 80C. Bacterial DNA was extracted using a QIAmp Fast DNA Stool Mini Kit
(QIAGEN) with an additional 5-min bead-beating step using aMini-Beadbeater-16 (Biospec Products, OK, USA). Library preparation
for the Illumina MiSeq platform was performed by amplification of the V3-V4 region of the bacterial 16S ribosomal DNA gene using
forward primer: 50-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG and reverse primer: 50-GTCTCG
TGGGCTCGGAGATGTGTATAAGAGACAG GACTACHVGGGTATCTAATCC. Adaptor and barcode sequences for dual indices
were used as described by Illumina. PCR cleanup steps were performed using a QIAquick 96-PCR Cleanup Kit (QIAGEN, Germany),
and library quantification was performed using a KAPA Library Quantification Kit for Illumina platforms (KAPA Biosystems, MA, USA).
An Experion Automated Gel Electrophoresis System (Bio-Rad, CA, USA) was used to measure the DNA concentration and purity in
the pooled libraries. The 16S libraries were sequenced at Novagene (Beijing, China) and at the SBP sequencing core.
16S sequencing data processing
The original FASTQ files from Illumina 250 base-pair paired-end sequencing were processed using a 16S amplicon sequencing pipe-
line HiMap (http://github.com/taolonglab/himap; BioRxiv 565572). The output of HiMap is Operational Strain Unit (OSU) which con-
tains one or more bacterial strains that best match the 16S sequence and cannot be further distinguished. The percentage similarity
between the 16S sequence and the aligned region of 16S rRNA genes of the strains in the OSU is indicated. OSUs mapped to the
same strains are grouped together (adding read counts) if percentage similarities are within 3%. Read counts are converted into rela-
tive abundance as described in HiMap. Log10-transformed relative abundances were used for comparisons between samples under
different experimental conditions. The raw 16S sequencing data is available as BioProject PRJNA593851 online at: https://www.
ncbi.nlm.nih.gov/bioproject/PRJNA593851.
Taxa selection
Taxa that distinguishedmicrobiota of inulin- ormucin-treatedmice from control micewere selected into three sets as follows. (1) Taxa
induced by inulin or mucin were selected by performing a paired one-tail Wilcoxon rank-sum test on the log10-transformed relative
abundances of all OSU groups in mice treated with prebiotics at time point B (after the start of prebiotic treatment and before tumor
injection) compared with time point A (before prebiotic treatment) with abundance at time point B greater than time point A. Taxa with
p values less than 0.05were selected as set 1. (2) A similar selection to (1) wasmade for data from the control mice. Taxawith p values
less than 0.2 were selected as set 2. This set contains taxa that were induced in the control group from time point A to time point B. (3)
The third set of OSU groups were selected by calculating Spearman’s correlations between each of the OSU groups and tumor size
at time point B, and selecting groups with p values less than 0.1. The final set of inulin- or mucin-induced taxa was selected as the
difference between set 1 and set 2 intersected with set 3. These are the taxa induced in inulin- or mucin-treated mice, but not in con-
trol mice, and had relative abundances before tumor injection that negatively correlated with tumor size at tumor collection. For anal-
ysis of mice treated with MEKi in combination with prebiotics, OSU groups in the fecal samples of mice treated with prebiotics alone
or in combination with MEKi were compared at time point D (final time point before tumor collection) with unpaired two-sided
Wilcoxon rank-sum test. OSU groups with p values less than 0.05 were selected for calculating Spearman’s correlations with tumor
size at time point D. The OSU groups with correlation p values less than 0.1 were selected as the differential taxa that were negatively
correlated with tumor size.
Tumor digestion
Tumors were excised, minced, and digested with 1 mg/mL collagenase D (Roche) and 100 mg/mL DNase I (Sigma) at 37C for 1 h.
Digests were then passed through a 70-mm cell strainer to generate a single-cell suspension. The cells were washed twice with PBS
containing 2 mM EDTA and then stained for flow cytometry.
Flow cytometry
Tumor-derived single-cell suspensions were washed twice with FACS staining buffer, fixed for 15 min with 1% formaldehyde in
PBS, washed twice, and resuspended in FACS staining buffer. For intracellular cytokine staining, cells were resuspended in
complete RPMI-1640 (containing 10 mM HEPES, 1% non-essential amino acids and L-glutamine, 1 mM sodium pyruvate, 10%
heat-inactivated FBS, and antibiotics) supplemented with 50 U/mL IL-2 (NCI) and 1 mg/mL brefeldin A (BFA, Sigma), and then incu-
bated with phorbol myristate acetate (10 ng/mL) and ionomycin (0.5 mg/mL) at 37C. The cells were fixed and permeabilized using a
Cytofix/Cytoperm Kit (BD Biosciences) before staining. Antibodies to the following proteins were used: CD45.2 (104), CD8a (53-6.7),
CD4 (GK1.5), CD44 (IM7), TNF-a (MP6-XT22), IFN-g (XMG1.2), CD11c (N418), CD11b (M1/70), MHC class II (M5/114.15.2), PDCA
(129c1), and B220 (RA3-6B2) (all from BioLegend), IL-2 (JES6-5H4) and MHC class I (AF6-88.5.5.3) (both from eBioscience). All
data were collected on an LSRFortessa (BD Biosciences) and analyzed using FlowJo Software (Tree Star).
Mucin and inulin treatment
For mucin treatment, C57BL/6, C3H/HeOuJ or GF ASF-bearing C3H/HeN mice (male, 68 weeks old) were provided with drinking
water with or without 3% mucin (Lee Biosolutions) starting 14 days before tumor inoculation. Water was changed every other day.
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For inulin treatment, C57BL/6 or C3H/HeOuJ mice (male, 68 weeks old) received standard chow (TD. 94048, AIN-93M, Purified
Diet, ENVIGO), standard chow enriched with long-chain inulin by substituting all sucrose and 5% of corn starch, or a modified
chow (TD. 160256, Modified AIN-93M, Diet with 15% inulin, ENVIGO) starting 14 days before tumor inoculation. Chowwas refreshed
two times a week.
RNA extraction and qRT-PCR analysis
Total RNA was extracted from tumor samples using an RNeasy Fibrous Tissue Midi Kit (QIAGEN) or from cells using a High Capacity
Reverse Transcriptase Kit (Invitrogen), according to the manufacturers’ protocols. Purity and concentration of extracted RNA were
determined by reading at 260 and 280 nm in a NanoDrop spectrophotometer (Thermo Fisher). qRT-PCR analysis was performed
using a SYBR Green RT-PCR Kit (Invitrogen) on a Bio-Rad CFX Connect Real-Time system. Expression levels were normalized to
18S or Tubb5 levels. The sequence-specific primers used in this study are shown in Table S4.
BMDCs
BM cells were isolated from the tibiae and femurs of C57BL/6 mice and cultured in DMEM medium containing 10% FBS, 1% peni-
cillin/streptomycin, and recombinant mouse GM-CSF (20 ng/mL; BioLegend) for 8 days at 37C.
Isolation of IECs
A 10-cm section of mouse small intestine was opened longitudinally, minced, washed in 150 mM NaCl containing 1 mM DTT, and
then resuspended in dissociation buffer (130 mM NaCl, 10 mM EDTA, 10 mM HEPES [pH 7.4], 10% FCS, and 1 mM DTT). The sec-
tions were incubated at 37C for 30 min with vigorous shaking to release the IECs from the lamina propria. The IEC suspension was
then carefully aspirated, centrifuged, and washed in ice-cold PBS.
Serum cytokine and chemokine detection
Serum cytokines and chemokines were quantified using the LEGENDplexTM mouse inflammation panel and mouse proinflammatory
chemokine panel (BioLegend), respectively. All data were collected on an LSRFortessa and analyzed using LEGENDplexTM software
(BioLegend).
In vivo antibody treatments
Mice were injected i.p. with 200 mg anti-PD-1 (clone RMP1-14) or rat IgG2a isotype control on days 7, 10, 13, and 16 after tumor
inoculation. All mAbs for in vivo use were GoInVivo grade from BioLegend. CD4+ and CD8+ T cells were depleted by i.p. injection
of 400 mg anti-mouse Thy1.2 (CD90.2, clone 30H12 from Bio X Cell) or rat IgG2b isotype control. Antibodies were injected two times
aweek starting on day 3 after tumor inoculation. The efficacy of depletion was assessed by FACS analysis of blood samples collected
on day 8 after tumor inoculation.
In vivo OT-I T cell proliferation assay
CD8+ T cells were isolated from the spleens of naive OT-I CD45.1+ mice, labeled with CFSE, and injected i.v. into WT CD45.2+
C57BL/6 mice treated with or without mucin. After 24 h, the mice were injected s.c. with 1 3 106 B16-OVA melanoma cells. Seven
days later, the spleen, tumor-draining lymph nodes, and non-draining lymph nodes were harvested and analyzed by flow cytometry.
The proliferation of OT-1 CD8+ T cells was assessed by analysis of CFSE dilution within the population by gating on CD45.1+ CD8+
T cells.
CD8+ T cell enrichment
CD8+ T cells were enriched by negative selection (StemCell Technologies, Inc.) according to the manufacturer’s instruction from
spleens of C57BL/6mice that were untreated or treated with mucin or inulin for 2 weeks. Briefly, the enrichment of mouse CD8+ naive
T cells utilized a biotinylated antibody cocktail (Biotinylated CD4, CD11b, CD11C, CD19, CD24 and B220 antibodies) that were
captured on streptavidin-coatedmagnetic beads. Pre-incubation of cells with the antibody cocktail-boundmagnetic beads enriched
the CD8+ T cells in solution. The purity of the enriched CD8+ T was confirmed by flow cytometry (> 95%). FACS analysis was per-
formed using FlowJo software.
QUANTIFICATION AND STATISTICAL ANALYSIS
Unless otherwise noted, all data are shown as the mean ± s.e.m. Before statistical analysis, data were subjected to the Kolmogorov–
Smirnov test to determine distribution. Variance similarity was tested using an F test for two groups and Bartlett’s test for multiple
groups. Two groups were compared using the two-tailed t test for parametric data or the Mann–Whitney U test for non-parametric
data. Multiple groups were compared using one-way ANOVA with Tukey’s, Dunnett’s, or Bonferroni’s correction for parametric data
or using the Kruskal–Wallis test with Dunn’s correction for non-parametric data. Tumor growth curves were analyzed using two-way
ANOVA with Sidak’s, Tukey’s, or Bonferroni’s correction for multiple comparisons. Statistical details of each experiment are indi-
cated in the corresponding figure legends.
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DATA AND CODE AVAILABILITY
The approach used to map microbiota taxa (Figures 5, 6, and S4) is detailed at: http://github.com/taolonglab/himap; BioRxiv
565572. The microbiome sequence data used for mapping the microbiota taxa have been deposited in NCI BioProject:
PRJNA593851 https://www.ncbi.nlm.nih.gov/bioproject/PRJNA593851. The raw data of this manuscript was deposited online
in the Mendeley archive https://data.mendeley.com/datasets/zrjr39f7mb/draft?a=28ed04b4-6d90-4eec-be59-c42e05589ade.
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